Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com

Biotechnology

Clinical Trials

Life Sciences

Therapeutics

Parabilis Medicines

Parabilis Medicines' headquarters in Cambridge, United States

Mathai Mammen, M.D., Ph.D.

Krishna Yeshwant

Richa Poddar

Nicolas Mourier

Marie Nguyen

Amanda Garofalo

Thomas Kotarakos

Teresa Jurgensen

Corey S. Goodman

Rohin Mhatre

Kristen Stants

John Mcgee

Greg Miller

Brandon Allgood

Parabilis Medicines

Org chart

Teams

Offices

Similar companies